Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lesion load may predict long-term cognitive dysfunction in multiple sclerosis patients.
Patti F, De Stefano M, Lavorgna L, Messina S, Chisari CG, Ippolito D, Lanzillo R, Vacchiano V, Realmuto S, Valentino P, Coniglio G, Buccafusca M, Paolicelli D, D'Ambrosio A, Montella P, Brescia Morra V, Savettieri G, Alfano B, Gallo A, Simone I, Viterbo R, Zappia M, Bonavita S, Tedeschi G. Patti F, et al. Among authors: chisari cg. PLoS One. 2015 Mar 27;10(3):e0120754. doi: 10.1371/journal.pone.0120754. eCollection 2015. PLoS One. 2015. PMID: 25816303 Free PMC article.
A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™-the FUTURE study.
Ghezzi A, Bianchi A, Baroncini D, Bertolotto A, Malucchi S, Bresciamorra V, Lanzillo R, Milani N, Martinelli V, Patti F, Chisari C, Rottoli M, Simone M, Paolicelli D, Visconti A; FUTURE Study Group. Ghezzi A, et al. Neurol Sci. 2017 Nov;38(11):1999-2005. doi: 10.1007/s10072-017-3091-6. Epub 2017 Aug 22. Neurol Sci. 2017. PMID: 28831635
Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
Comi G, Patti F, Rocca MA, Mattioli FC, Amato MP, Gallo P, Centonze D, Pozzilli C, Saccà F, Bergh FT, Bartezaghi M, Turrini R, Filippi M; Golden Study Group. Comi G, et al. J Neurol. 2017 Dec;264(12):2436-2449. doi: 10.1007/s00415-017-8642-5. Epub 2017 Oct 23. J Neurol. 2017. PMID: 29063244 Free PMC article. Clinical Trial.
98 results